IL-19 is an anti-inflammatory marker37 and diminishes cerebral infarction and neurological deficits following cerebral ischemia in mice, potentially through the elevated expression of genes related to proinflammatory cytokines.38 As increased IL-19 levels appear to be an anti-inflammatory marker, and increased TNFRSF14 levels show a role in immune cell survival,39 this leads to the notion of inflammation as a contributor to subsequent MACE outcomes. Here, TNFRSF14 is linked to brain ischemia.